EP1817044A1 - Composition comprenant un polysaccharide dote d'une action de blocage de bacteries - Google Patents

Composition comprenant un polysaccharide dote d'une action de blocage de bacteries

Info

Publication number
EP1817044A1
EP1817044A1 EP05813977A EP05813977A EP1817044A1 EP 1817044 A1 EP1817044 A1 EP 1817044A1 EP 05813977 A EP05813977 A EP 05813977A EP 05813977 A EP05813977 A EP 05813977A EP 1817044 A1 EP1817044 A1 EP 1817044A1
Authority
EP
European Patent Office
Prior art keywords
composition
accordance
bacteria
streptococcus
spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05813977A
Other languages
German (de)
English (en)
Inventor
Alexander James Hanbury Duggan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Passion for Life Healthcare Ltd
Original Assignee
Passion for Life Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Passion for Life Healthcare Ltd filed Critical Passion for Life Healthcare Ltd
Publication of EP1817044A1 publication Critical patent/EP1817044A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a composition for the preparation of an isotonic or hypertonic formulation comprising an active ingredient, a process for the preparation thereof and the use thereof for delivery to the ear, nose or eye of a human or animal.
  • Sea water isotonic sprays are known as hygiene prevention products, in particular sprays for the ear to disperse earwax and nasal douches for general nasal hygiene. Such sprays comprise no active therapeutically ingredients.
  • Sprays exist incorporating antibiotics to combat bacterial infection, however these have the usual disadvantages associated with antibiotics e.g. are not recommended for prolonged use, are associated with side effects and can lead to immunity of bacteria and subsequent ineffectiveness of the composition.
  • + sterilized extract include: antibacterial, seawater by antifungal, antiviral, micro filtration antioxidant, anticarcmogenic, antithrombotic, immunomodulatory
  • Hypertonic seawater seawater solution acts solution like a natural decongestant
  • RJtiino- Spray Weleda Physiological aloe vera contains Aloe Vera gel doron saline solution in an isotonic salt solution. This means that the salt content of the solution is adjusted to match the body's fluids, so the solution is well tolerated by the mucous membranes
  • Poli Bimbi Spray ???, Italy Physiological liposome a spherical particle of solution fat suspended in a liquid medium. They may be used to carry drugs or other substances to cells or tissues
  • Neo baby vials ???, Italy Sterile physiological solution
  • Marplus spray Germany seawater dexpanthenol claimed to be pre-cursor of coenzyme A Usually administered intraven ⁇ ously or intramusculary but can also be applied topically to the skin to stimulate healing of of various dermatologic lesions such as burns, infected wounds, eczema etc.
  • Otrisalin Spray 111 Greece purified water sodium when added to water chloride (0.09%), makes it a physiological solution.
  • Vitaprolis Spray 111 france sterilised propolis Possible actions: seawater extract antibacterial, antifungal, antiviral, antioxidant, anticarcinogenic, antithrombotic, immunomodulatory
  • seawater extract antibacterial, antifungal, antiviral, antioxidant, anticarcinogenic, antithrombotic, immunomodulatory we have now found that a certain class of active ingredients which are useful in combating bacteria by a bacterial blocking action are free from side effects and immunity. Moreover we have found that such products are ideally suited to a preventitive hygiene use.
  • compositions of an isotonic or hypertonic formulation or a powder for the preparation thereof comprising an active ingredient which is effective in blocking harmful bacteria, which composition may be used for the manufacture of a medicament which is effective in blocking adhesion of harmful bacteria to host tissues, the composition comprising an isotonic or hypertonic formulation or a powder for the preparation thereof including an active bacteria blocking ingredient selected from extracts of plant or animal origin and/ or derivatives thereof comprising a combination of polysaccharides comprising 60-100% of D-mannose, 40-0% of D-glucose and 0- 10% of other monosaccharides.
  • the isotonic or hypertonic formulation of the composition of the invention may be saline or desalinated and in one alternative is preferably a sea water or a desalinated fluid. Such formulations have known benefits in cleansing ears, nose and eyes with minimal disruption to the mucosa.
  • an identified osmo-protectant (this is, a species known to mitigate the effect of osmosis between calls and the outside world) may be used, for example being trimethy glycine.
  • antibiotic compositions that have antibacterial effect and bacteria blocking compositions.
  • An active ingredient effective in blocking harmful bacteria is effective in blocking adhesion of such bacteria to host tissues.
  • Active ingredients are known which are effective in preventing adhesion of harmful bacteria to host tissues, and in particular extracts of plant or animal origin, which term includes derivatives, compounds and mixtures of such extracts.
  • extracts/ derivatives comprise polysaccharides derivable from the plant or animal and mixtures thereof. In particular they comprise a combination of polysaccharides comprising 60-100% of D-mannose, 40-0% of D- glucose and 0-10% of other monosaccharides.
  • Such active ingredients are in particular selected from extracts and/ or derivatives of aloe, in particular aloe vera and derivatives thereof.
  • a bacteria blocking active ingredient is negatively charged.
  • a bacteria blocking active ingredient extract is known from PCT/NL02/00868 (WO03/055918). That is to say, ascribed therein the active ingredient comprises negatively charged polysaccharides derivable from Aloe vera in a mixture 60-100% D-mannose, 40-0% D-glucose and 0-10% other monosaccharides and with an average molecular weight higher than 50 kD, for example about 100-300 kD.
  • the mixture comprises 70-90% D-mannose, 30-10% D-glucose and 0-10% other monosaccharides.
  • the mixture comprises D-mannose and D-glucose in a ratio of a range of about 5 to 20.
  • the composition may be delivered in any known manner and is preferably delivered as a spray, douche or equivalent which has the effect of drenching the surface tissue of a recipient.
  • the composition is for delivery to the ear, nose or eyes of a human, non-human mammal or animal host.
  • the composition of the invention is effective in administering to combat ear, nasal or eye sanitary hygiene conditions such as the build up of earwax, nasal mucus, cleansing of the eye and the like. It is a particular advantage that the composition of the invention may prevent inflammation and bacterial infections such as conjuctivitis or by bacteria such as MRSA (Methicillin Resistant Staphylococcus Aureus) and the like.
  • infections of the eye, ear, nose and throat which can be prevented and treated by anti adhesive polysaccharides of the present invention include those caused by:
  • Staphylococcus epidermis which plays an important role in the pathogenesis of some forms of endophthamitis occurring after cataract surgery
  • Moraxella bovis as the source of infectious bovine keratoconjunctivitis Staphylococcus aureus which adheres to the skin and mucous tissues
  • Periodontopathogenic bacteria such as Porphyromonas gingivalis and Streptococcus salivarius, Streptococcus oralis, Fusobacterium nucleatum and Prevotella intermedia
  • the composition may include additional active ingredients, for example effective in combating snoring or apnoea dry eyes, irritated or tired eyes, decongestion, hay fever, allergy or tinnitus.
  • the composition may include any suitable additional ingredients such as excipients, stabilisers, carriers, fillers and the like.
  • the composition includes a humectant for example pentylene glycol.
  • the composition includes up to 10 Wt % humectant where present, for example 1 — 5 Wt %.
  • the bacteria blocking active ingredient is present in any effective blocking amount, preferably in the range 1 - 20 Wt % and for example 2 - 10 Wt %.
  • the composition may be suitable for delivery by any known effective means and is preferably suitable for delivery by a spray dispenser, including a nasal, eye or eye spray dispenser, by pipette, as a wash, such as an eye wash or ear wash or a wash for nasal inhalation and the like.
  • a spray dispenser including a nasal, eye or eye spray dispenser, by pipette, as a wash, such as an eye wash or ear wash or a wash for nasal inhalation and the like.
  • Suitable spray dispensers are known in the art and include pump spray dispensers comprising a reservoir fluidly connected to spray delivery means which are adapted to draw, aerosolise and deliver a controlled dose from the reservoir to a subject in use.
  • a dispenser for delivery to the ear has a barrier to prevent overinsertion.
  • a spray dispenser for dispensing to the ear comprises a dispersement nozzle suitable to provide a disperse jet to avoid ear drum damage.
  • composition of the invention is provided as a solution, liquid, gel, ointment, suspension or the like or powder form to mix with fluid.
  • an active ingredient as hereinbefore defined which is effective in blocking harmful bacteria for use in a spray composition as hereinbefore defined and/ or in the manufacture of a medicament as hereinbefore defined.
  • a method of blocking adhesion of harmful bacteria to host tissues of a human, non-human mammal or animal host comprising applying an isotonic or hypertonic formulation including an active bacteria blocking ingredient selected from extracts of plant or animal origin and/ or derivatives thereof comprising a combination of polysaccharides comprising 60- 100% of D-mannose, 40-0% of D-glucose and 0-10% of other monosaccharides.
  • the method comprises applying the isotonic or hypertonic formulation to the ear, nose or eyes of the host.
  • the method comprises drenching the surface tissue of a recipient by delivering the composition as a spray or as a douche.
  • the method is in particular a method for the prevention and/ or treatment of inflammation and bacterial infections, including those caused by:
  • Staphylococcus aureus including MRSA, which adheres to the skin and mucous tissues; bacteria involved in Otitis media and nasopharyngal comprising Haemophilus influenza, Streptococcus penumoniae and Moraxella catarrhalis ; bacteria involved in caries such as Streptoccoccus sobrinus as acariogenic strain,
  • Streptocossus mutans Streptococcus salivarius, Streptococcus gordonii and
  • Actinomyces viscosus Actinobacillus actinomycetecomitans
  • periodontopathogenic bacteria comprising Porphyromonas gingivalis and Streptococcus salivarius, Streptococcus oralis, Fusobacterium nucleatum and Prevotella intermedia
  • all oral spirochetes which are classified in the genus Treponema, comprising denticola, pectinovorum, socranskii and vincentii
  • Mycoplasma salivarium microorganisms involved in nasal polyposis
  • microorganisms involved in Sinusitis any combination of the gingivalis and Streptococcus salivarius
  • Streptococcus oralis Fusobacterium nucleatum and Prevotella intermedia
  • all oral spirochetes which are classified in the genus Treponema, comprising denticola, pectinovorum, socranskii and vincentii
  • Composition 1 Isotonic Nasal/ Aural spray
  • trimethylglycine The conventional role of sodium chloride is taken by betaine (trimethylglycine).
  • betaine trimethylglycine
  • One of the properties of trimethylglycine is that it avoids osmosis between cells and the outside world due to differences in electrolyte concentration, and trimethylglycine is therefore identified as an osmo-protectant.
  • the polysaccharide constituent is a negatively charged mixture of 70-90% D- Mannose 30-10% glucose, and 0-10% of other monosaccharides and is a plant derivative, for example Aloe Vera derivative.
  • pentylene glycol contributes to the required humectancy. At the same time pentylene glycol assures optimal protection of the consumer product while maintaining the mucous membrane integrity.
  • eyebright extract in the nasal spray.
  • eyebright is used to treat nasal mucous membrane inflammation, allergies, allergic rhinitis, common cold, bronchial conditions and sinusitis. It also used orally for conjuctivitis, earaches, headaches, hoaresness, opthalmia, rhinitis, skin aliments, and sore throat. Eyebright is also used topically to prevent mucous and mucous membrane inflammation of the eyes. Eyebright is considered safe when used orally and appropriately. Eyebright is listed by the Council of Europe as a natural source of food flavouring.
  • the osmotic pressure of the solute is higher than in the cells. Higher osmotic pressure is achieved by a higher electrolyte loading.
  • Using a hypertonic spray may enable drainage of excessive liquid from the cells, to reduce swellings, for the treatment of sinusitis, headaches and nasal congestion.
  • sodium chloride or sea water
  • betaine This maintains the original equilibrium but also effects a raising of the osmotic pressure from the cells to the environment, therefore reducing swelling.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition d'une formulation isotonique ou hypertonique ou une poudre destinée à la préparation de celle-ci, la composition comprenant un principe actif capable de bloquer des bactéries nocives et sélectionné parmi des extraits de plante ou d'origine animale et/ou des dérivés de celui-ci comprenant une combinaison de polysaccharides comprenant entre 60 et 100 % de D-mannose, 40 et 0 % de D-glucose et 0 et 10 % d'autres monosaccharides. L'invention concerne également un principe actif capable de bloquer des bactéries nocives à utiliser dans une composition de pulvérisation ou de douche, de manière à imbiber le tissu de surface d'un destinataire; l'utilisation d'une composition dans le blocage de l'adhésion de bactéries nocives sur des tissus hôtes; et l'utilisation d'une composition dans la fabrication d'un médicament ayant un tel effet.
EP05813977A 2004-11-29 2005-11-29 Composition comprenant un polysaccharide dote d'une action de blocage de bacteries Withdrawn EP1817044A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0426068.3A GB0426068D0 (en) 2004-11-29 2004-11-29 Composition with bacteria blocking action
PCT/GB2005/004555 WO2006056801A1 (fr) 2004-11-29 2005-11-29 Composition comprenant un polysaccharide dote d'une action de blocage de bacteries

Publications (1)

Publication Number Publication Date
EP1817044A1 true EP1817044A1 (fr) 2007-08-15

Family

ID=33561445

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05813977A Withdrawn EP1817044A1 (fr) 2004-11-29 2005-11-29 Composition comprenant un polysaccharide dote d'une action de blocage de bacteries

Country Status (3)

Country Link
EP (1) EP1817044A1 (fr)
GB (1) GB0426068D0 (fr)
WO (1) WO2006056801A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2906472B1 (fr) * 2006-09-29 2008-12-26 Goemar Lab Sa Solutions ioniques hypertoniques a base d'eau de mer non diluee, leur utilisation en tant que medicaments et pour la preparation de medicaments destines au traitement de la congestion nasale.
ITMI20071051A1 (it) * 2007-05-24 2008-11-25 Farmaceutici S R L Composizione per il trattamento naturale e/o di sintesi, delle patologie infiammatorie batteriche o virali della gola, con presenza di xerostomia.
RU2607892C2 (ru) * 2012-05-25 2017-01-11 Экслиар, Инк. Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции
US20140356460A1 (en) * 2013-05-28 2014-12-04 Matthew Lutin Use of hypertonic saline to draw fluid out of swollen tissue and relieve nasal congestion
US10456353B2 (en) 2014-04-17 2019-10-29 Conopco, Inc. Personal care compositions
EA201692085A1 (ru) 2014-04-17 2017-02-28 Юнилевер Н.В. Экстракт алоэ (aloe vera) для композиций, применяемых в личной гигиене
EP2985019B1 (fr) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Composition nasale ayant des propriétés antivirales
EP2985027B1 (fr) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Composition nasale renfermant un mélange d'acides hyaluroniques et une solution saline
JP2023549288A (ja) * 2020-10-21 2023-11-22 ２キューアール・リサーチ・ベスローテン・フェンノートシャップ 微生物中和のためのアロエ抽出物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290964B1 (en) * 1998-03-06 2001-09-18 Kathleen Shupe Antimicrobial agents isolated from aloe vera
EP1323738A1 (fr) * 2001-12-27 2003-07-02 2QR Research BV Polysaccharide chargé négativement extrait d'Aloé vera
GB0230042D0 (en) * 2002-12-23 2003-01-29 Britannia Pharmaceuticals Ltd Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006056801A1 *

Also Published As

Publication number Publication date
WO2006056801A1 (fr) 2006-06-01
GB0426068D0 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2006056801A1 (fr) Composition comprenant un polysaccharide dote d'une action de blocage de bacteries
ES2611351T3 (es) Formulación para tratamiento tópico de heridas
ES2949139T3 (es) Composición que elimina la congestión nasal y que tiene actividad antivírica
CN105148253B (zh) 皮肤黏膜抗菌组合物
US20060105000A1 (en) Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
US20060280809A1 (en) Anti-infective iodine based compositions for otic and nasal use
TW201538181A (zh) 用於潤滑保濕消毒滅菌之半流體組成物及其使用方法
DK2613793T3 (en) NOSE SPRAY
CA2924059C (fr) Compositions therapeutiques et fabrication et utilisation associees
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
KR20150113035A (ko) 표면 상처의 치료를 위한 조성물 및 방법
ES2724529T3 (es) Composición antiséptica
ES2860098T3 (es) Composición para la aplicación nasal
WO2015082965A2 (fr) Nouveau lavage nasal au chitosane
SE1650162A1 (en) Antimicrobial and cleansing composition comprising a polymeric biguanide, EDTA, and surfactants.
CN102861206A (zh) 皮肤粘膜杀菌消毒气雾剂及其制备方法
ES2787776T3 (es) Composición para el tratamiento de la cavidad de la garganta/orofaringe
RU2184538C2 (ru) Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт
EP2313089A2 (fr) Produit polyvalent pour application nasale chargé électrostatiquement et procédé associé
US11576926B2 (en) Composition for use in the prevention and/or treatment of epistaxis
DK181405B1 (en) Gel for Intranasal Application, its Provision and Use
US11878032B2 (en) Aqueous saline composition, process for the production of same, and use of same
TW201722395A (zh) 遠紅外線潔牙凝膠
WO2024016109A1 (fr) Composition de soins buccaux à base d'une substance active du thé et son procédé de préparation
EP4368178A1 (fr) Compositions et leurs utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20081203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090415